News

Reel change after change of scene
Enlarge image

BiopeopleUKAustria

Reel change after change of scene

15.05.2012 - F-Star's management has been lifted and replaced by a troika of new leaders.

Cambridge  - A press note issued by Austrian-British F-Star GmbH on 14 May names the new personnel. Following Keith Fitz-Gerald as CEO is John Haurum who had been CSO of the Danish biotechnology company Symphogen A/S. Also quickly appointed: Jane Dancer and Sharon Grimster. Dancer was previously employed at Cellzome Ltd. At F-Star she becomes Chief Operating Officer (COO).  Grimster, formerly employed at Antisoma plc, has been appointed Vice President of Development.

Clearing the management board so vigorously  is indeed a surprise, even with the knowledge that the company - a leader in the development of bispecific antibodies - has had a hard time after moving all research operations from Vienna to Cambridge leaving the parent company in Austria. The Supervisory Board did not forget to mention Kevin FitzGerald and thanked him for "his significant contribution in bringing F-star to its current stage of development". He started as the company's CEO in May 2009. Within this three years, the start-up saved €23m using venture financing. He also arranged major alliances with Boehringer Ingelheim and Merck Serono.


With its proprietary technology, F-star produces antibody fragments called Fcabs, which have full antibody capabilities but are believed to have a better biological profile because of their small size. Additionally Fcabs may offer IP advantages in many cases by lacking variable regions, which may be claimed by third party antibody patents. This seems to attract pharma companies. In November 2010, F-star allied with Germany's Boehringer Ingelheim and in September 2011 with Merck Serono.

http://www.european-biotechnology-news.com/news/news/2012-02/reel-change-after-change-of-scene.html

BusinessUK

03.03.2015 After weeks of speculation, AstraZeneca has announced its plans to spin out its early-stage antibiotic R&D. The decision marks the company’s aims to “sharpen its focus on three main therapy areas”.

GenericsEUUKHungaryGermanyItalyGreeceAustriaLuxembourgFranceSpain

26.02.2015 It is the first biosimilar monoclonal antibody in many European markets: Mundipharma and Hospira are launching Celltrion’s Remicade generic.

M&AUK

23.02.2015 British drug developer Heptares has been acquired by Japanese biopharma play Sosei for US$400m (€352m).

bioethanolGermanyUKBelgiumFrance

19.02.2015 The price of oil has been sliding for months, and the European bioethanol market is taking it hard. CropEnergies AG has now stopped production at its British unit Ensus UK.

BusinessFranceGermany

17.02.2015 After Christopher Viehbacher’s unceremonious ousting last year, Sanofi has been on the look out for a new CEO. Now, sources say Bayer’s Olivier Brandicourt is set to fill the position.

BusinessUKSwitzerland

12.02.2015 Glaxosmithkline is intent on bolstering its vaccine portfolio further and has bought all shares of Swiss development partner Glycovaxyn.

InvestmentsUKEU

10.02.2015 Interest in biotechnology is on the rise among British investors. Not just one, but two major financiers are planning investment funds in the field.

IVFUKEU

04.02.2015 In a historic move, the UK is set to become the first country to allow the creation of babies with the genetic material of three people – a mother, a father and a female mitochondrial donor.

Events

All Events

Partner-Events

Planegg/Martinsried

1st Munich Biotech Pitch

Berlin (DE)

Proteomic Forum 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CYTOS0.36 CHF5.88%
  • MERCK KGAA94.27 EUR2.25%
  • STRATEC BIOMEDICAL46.09 EUR1.97%

FLOP

  • VITA 345.55 EUR-3.48%
  • EVOTEC3.75 EUR-2.60%
  • MOLOGEN5.26 EUR-2.59%

TOP

  • WILEX3.15 EUR57.5%
  • THERAMETRICS0.07 CHF16.7%
  • BASILEA120.00 CHF15.2%

FLOP

  • SANTHERA96.30 CHF-16.6%
  • 4SC0.78 EUR-14.3%
  • MOLOGEN5.26 EUR-13.2%

TOP

  • SANTHERA96.30 CHF2434.2%
  • WILEX3.15 EUR433.9%
  • FORMYCON16.23 EUR100.9%

FLOP

  • CYTOS0.36 CHF-87.8%
  • MOLOGEN5.26 EUR-56.7%
  • BIOFRONTERA1.92 EUR-51.3%

No liability assumed, Date: 02.03.2015